GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Small and Large Bowel/DGBI and Carbohydrate intolerance
95

DGBI and Carbohydrate intolerance

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated August 1, 2025

Disorders of Gut-Brain Interaction (DGBI) and Carbohydrate Intolerance:

Overview of DGBI:

Disorders of Gut-Brain Interaction (DGBI) encompass a group of conditions characterized by abnormal communication between the gut and the brain. These disorders include conditions such as irritable bowel syndrome (IBS), functional dyspepsia, and functional constipation, among others. DGBI are not caused by structural abnormalities or diseases but rather by dysfunction in the gut-brain axis, leading to symptoms like abdominal pain, bloating, diarrhea, constipation, and altered bowel habits.

Carbohydrate Intolerance in DGBI:

Carbohydrate intolerance is a condition where the body has difficulty digesting certain types of carbohydrates, such as lactose (milk sugar) and fructose (fruit sugar). In a French study of 301 adults with DGBI, carbohydrate intolerance was found to be highly prevalent:

  • Prevalence: More than half (59%) of the participants had carbohydrate intolerance, involving lactose, fructose, or both. Additionally, 44% showed evidence of carbohydrate malabsorption on breath testing.
  • Breakdown of Intolerance:
  • 47 patients were intolerant to lactose only.
  • 54 patients were intolerant to fructose only.
  • 77 patients were intolerant to both lactose and fructose.

Who Is Most Affected?

  • Gender: Women were more likely to have carbohydrate intolerance compared to men.
  • Multiple DGBIs: Patients with multiple DGBI conditions were also more likely to experience carbohydrate intolerance.

Clinical Impact:

Carbohydrate intolerance in DGBI patients was associated with worse clinical outcomes:

  • Worsened IBS Symptoms: Patients with carbohydrate intolerance experienced more severe IBS symptoms compared to those without intolerance.
  • Somatic Complaints: These individuals reported more somatic complaints, which are physical symptoms not explained by underlying organic disease (e.g., fatigue, headaches, muscle pain).
  • Lower Quality of Life: Carbohydrate intolerance negatively impacted patients' overall quality of life.

Key Findings:

  • Lactose Maldigestion: Lactose maldigestion was strongly linked to carbohydrate intolerance and correlated with the severity of somatic symptoms.
  • Fructose Malabsorption: Fructose malabsorption alone was not significantly associated with worse symptoms or somatic complaints.

Implications for Management:

Carbohydrate intolerance is common in DGBI and contributes to the severity of symptoms. Identifying and addressing carbohydrate intolerance, particularly lactose-related intolerance, may help guide personalized treatment strategies. For example:

  • Dietary Adjustments: Eliminating or reducing problematic carbohydrates (e.g., lactose or fructose) from the diet may alleviate symptoms.
  • Improved Quality of Life: Targeted dietary interventions can potentially improve the quality of life for DGBI patients.

Conclusion:

Carbohydrate intolerance plays a significant role in exacerbating symptoms and reducing the quality of life in individuals with DGBI. Understanding the specific type of carbohydrate intolerance (lactose, fructose, or both) and tailoring management strategies accordingly could lead to better outcomes for these patients.

Related Q&A

96

Auto-Brewery Syndrome (ABS)

Auto-Brewery Syndrome (ABS), also referred to as gut fermentation syndrome, is a rare and likely underdiagnosed medical condition in which gut microbes (bacteria and/or yeast) ferment carbohydrates into...

97

Extra bacterial Gut Ecosystem

The gut ecosystem is predominantly composed of bacteria, but emerging research highlights the importance of other microbial entities, such as fungi and bacteriophages, which play crucial roles in...

98

Obefazimod (ABX464) in Ulcerative Colitis

Obefazimod, also known as ABX464, is a first-in-class small molecule with a novel mechanism of action specifically designed to treat moderate-to-severe ulcerative colitis (UC). Below is a detailed...

99

Binge Eating Disorder (BED)

Binge Eating Disorder (BED) is a serious and common eating disorder characterized by recurrent episodes of consuming large quantities of food in a short period, often accompanied by...

100

Auricular Vagus Nerve Stimulation in Constipation-Predominant IBS

Auricular vagus nerve stimulation (taVNS) has emerged as a promising non-invasive neuromodulation therapy for managing constipation-predominant irritable bowel syndrome (IBS-C). A randomized controlled trial has demonstrated that taVNS...

101

Intestinal Ultrasound–Defined Active IBD in Pregnancy and Adverse Obstetric Outcomes

The use of intestinal ultrasound (IUS) to monitor disease activity in pregnant women with inflammatory bowel disease (IBD) has been shown to have significant prognostic value in predicting...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer